Telemus Capital LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 31.2% during the second quarter, Holdings Channel reports. The firm owned 24,951 shares of the biopharmaceutical company’s stock after buying an additional 5,930 shares during the period. Telemus Capital LLC’s holdings in Pfizer were worth $879,000 as of its most recent filing with the SEC.
Other hedge funds have also recently made changes to their positions in the company. BlackRock Fund Advisors raised its stake in shares of Pfizer by 1.5% in the first quarter. BlackRock Fund Advisors now owns 92,489,121 shares of the biopharmaceutical company’s stock worth $2,741,378,000 after buying an additional 1,403,646 shares during the period. Wellington Management Group LLP raised its position in shares of Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock worth $2,454,601,000 after buying an additional 3,936,078 shares during the period. Franklin Resources Inc. raised its position in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares during the period. BlackRock Group LTD raised its position in shares of Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock worth $1,762,838,000 after buying an additional 3,154,116 shares during the period. Finally, Legal & General Group Plc raised its position in shares of Pfizer by 1.7% in the first quarter. Legal & General Group Plc now owns 29,385,795 shares of the biopharmaceutical company’s stock worth $871,079,000 after buying an additional 488,194 shares during the period. Hedge funds and other institutional investors own 69.65% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded down 0.27% on Friday, reaching $33.56. 14,819,706 shares of the company’s stock were exchanged. The firm has a market capitalization of $203.56 billion, a price-to-earnings ratio of 29.75 and a beta of 0.86. The firm has a 50-day moving average of $34.29 and a 200-day moving average of $34.19. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. Pfizer’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.56 EPS. On average, equities analysts expect that Pfizer Inc. will post $2.46 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.58%. The ex-dividend date is Tuesday, November 8th. Pfizer’s payout ratio is currently 95.24%.
A number of equities analysts have weighed in on PFE shares. Vetr upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price target on the stock in a report on Monday, June 27th. Deutsche Bank AG reiterated a “buy” rating and issued a $44.00 price target on shares of Pfizer in a report on Thursday, August 18th. Credit Suisse Group AG reiterated an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a report on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, August 23rd. Finally, Jefferies Group set a $41.50 price target on shares of Pfizer and gave the company a “buy” rating in a report on Thursday, July 14th. Ten investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Pfizer currently has an average rating of “Buy” and a consensus price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.